Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bethanechol with Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT05241249Phase 2Recruiting
- Start
- Feb 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bethanechol in pancreatic adenocarcinoma (PDAC). Primary endpoint: R0 resection rate at 36 months. Started Feb 2022; status: recruiting.
02
Drugs
bethanechol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05241249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241249.